U
Blonder Tongue Laboratories, Inc.
BDRL
$0.149
-$0.039-20.75%
D
Sell
6/30/2023Downgrade
Blonder Tongue Laboratories, Inc. (BDRL) was downgraded to D- from D on 6/30/2023 due to a decline in the total return index and volatility index.
Blonder Tongue Laboratories, Inc. (BDRL) was downgraded to D- from D on 6/30/2023 due to a decline in the total return index and volatility index.
D
Sell
6/15/2023Upgraded
Blonder Tongue Laboratories, Inc. (BDRL) was upgraded to D from D- on 6/15/2023 due to an increase in the volatility index.
Blonder Tongue Laboratories, Inc. (BDRL) was upgraded to D from D- on 6/15/2023 due to an increase in the volatility index.
D
Sell
5/31/2023Downgrade
Blonder Tongue Laboratories, Inc. (BDRL) was downgraded to D- from D on 5/31/2023 due to a decline in the volatility index and total return index.
Blonder Tongue Laboratories, Inc. (BDRL) was downgraded to D- from D on 5/31/2023 due to a decline in the volatility index and total return index.
D
Sell
4/21/2023Upgraded
Blonder Tongue Laboratories, Inc. (BDRL) was upgraded to D from E+ on 4/21/2023 due to an increase in the efficiency index, volatility index and valuation index. Net income increased 112.8% from -$703 to $90, and total capital increased 1.04% from $11.75M to $11.88M.
Blonder Tongue Laboratories, Inc. (BDRL) was upgraded to D from E+ on 4/21/2023 due to an increase in the efficiency index, volatility index and valuation index. Net income increased 112.8% from -$703 to $90, and total capital increased 1.04% from $11.75M to $11.88M.
E
Sell
4/14/2023Downgrade
Blonder Tongue Laboratories, Inc. (BDRL) was downgraded to E+ from D- on 4/14/2023 due to a decline in the volatility index and valuation index.
Blonder Tongue Laboratories, Inc. (BDRL) was downgraded to E+ from D- on 4/14/2023 due to a decline in the volatility index and valuation index.
D
Sell
3/29/2023Upgraded
Blonder Tongue Laboratories, Inc. (BDRL) was upgraded to D- from E+ on 3/29/2023 due to an increase in the valuation index, volatility index and total return index.
Blonder Tongue Laboratories, Inc. (BDRL) was upgraded to D- from E+ on 3/29/2023 due to an increase in the valuation index, volatility index and total return index.
E
Sell
3/14/2023Downgrade
Blonder Tongue Laboratories, Inc. (BDRL) was downgraded to E+ from D on 03/14/2023.
Blonder Tongue Laboratories, Inc. (BDRL) was downgraded to E+ from D on 03/14/2023.
D
Sell
2/9/2023Upgraded
Blonder Tongue Laboratories, Inc. (BDRL) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
Blonder Tongue Laboratories, Inc. (BDRL) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
E
Sell
2/8/2023Downgrade
Blonder Tongue Laboratories, Inc. (BDRL) was downgraded to E+ from D on 2/8/2023 due to a decline in the valuation index.
Blonder Tongue Laboratories, Inc. (BDRL) was downgraded to E+ from D on 2/8/2023 due to a decline in the valuation index.
D
Sell
11/28/2022Upgraded
Blonder Tongue Laboratories, Inc. (BDRL) was upgraded to D from D- on 11/28/2022 due to an increase in the total return index and volatility index.
Blonder Tongue Laboratories, Inc. (BDRL) was upgraded to D from D- on 11/28/2022 due to an increase in the total return index and volatility index.
D
Sell
11/11/2022Downgrade
Blonder Tongue Laboratories, Inc. (BDRL) was downgraded to D- from D on 11/11/2022 due to a decline in the growth index, total return index and solvency index. Debt to equity increased from 4.28 to 7.02.
Blonder Tongue Laboratories, Inc. (BDRL) was downgraded to D- from D on 11/11/2022 due to a decline in the growth index, total return index and solvency index. Debt to equity increased from 4.28 to 7.02.
D
Sell
5/16/2022Upgraded
Blonder Tongue Laboratories, Inc. (BDRL) was upgraded to D from E+ on 05/16/2022.
Blonder Tongue Laboratories, Inc. (BDRL) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
Blonder Tongue Laboratories, Inc. (BDR) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index and volatility index.
Blonder Tongue Laboratories, Inc. (BDR) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index and volatility index.
D
Sell
5/6/2022Upgraded
Blonder Tongue Laboratories, Inc. (BDR) was upgraded to D from D- on 5/6/2022 due to a major increase in the growth index, volatility index and valuation index. Operating cash flow increased 114.44% from -$540 to $78.
Blonder Tongue Laboratories, Inc. (BDR) was upgraded to D from D- on 5/6/2022 due to a major increase in the growth index, volatility index and valuation index. Operating cash flow increased 114.44% from -$540 to $78.
D
Sell
5/3/2022Downgrade
Blonder Tongue Laboratories, Inc. (BDR) was downgraded to D- from D on 5/3/2022 due to a decline in the volatility index and total return index.
Blonder Tongue Laboratories, Inc. (BDR) was downgraded to D- from D on 5/3/2022 due to a decline in the volatility index and total return index.
D
Sell
4/18/2022Upgraded
Blonder Tongue Laboratories, Inc. (BDR) was upgraded to D from D- on 4/18/2022 due to a large increase in the efficiency index and growth index. Operating cash flow increased 28.29% from -$753 to -$540.
Blonder Tongue Laboratories, Inc. (BDR) was upgraded to D from D- on 4/18/2022 due to a large increase in the efficiency index and growth index. Operating cash flow increased 28.29% from -$753 to -$540.
D
Sell
1/26/2022Downgrade
Blonder Tongue Laboratories, Inc. (BDR) was downgraded to D- from D on 1/26/2022 due to a large decline in the total return index and volatility index.
Blonder Tongue Laboratories, Inc. (BDR) was downgraded to D- from D on 1/26/2022 due to a large decline in the total return index and volatility index.
D
Sell
11/23/2021Upgraded
Blonder Tongue Laboratories, Inc. (BDRL) was upgraded to D from D- on 11/23/2021.
Blonder Tongue Laboratories, Inc. (BDRL) was upgraded to D from D- on 11/23/2021.
D
Sell
11/8/2021Downgrade
Blonder Tongue Laboratories, Inc. (BDR) was downgraded to D- from D on 11/8/2021 due to a decline in the volatility index and valuation index.
Blonder Tongue Laboratories, Inc. (BDR) was downgraded to D- from D on 11/8/2021 due to a decline in the volatility index and valuation index.
D
Sell
11/3/2021Downgrade
Blonder Tongue Laboratories, Inc. (BDR) was downgraded to D from D+ on 11/3/2021 due to a significant decline in the growth index and volatility index. EBIT declined 833.33% from -$9 to -$84, operating cash flow declined 597.22% from -$108 to -$753, and earnings per share declined from $0.1093 to -$0.02.
Blonder Tongue Laboratories, Inc. (BDR) was downgraded to D from D+ on 11/3/2021 due to a significant decline in the growth index and volatility index. EBIT declined 833.33% from -$9 to -$84, operating cash flow declined 597.22% from -$108 to -$753, and earnings per share declined from $0.1093 to -$0.02.
D
Sell
10/13/2021Upgraded
Blonder Tongue Laboratories, Inc. (BDR) was upgraded to D+ from D on 10/13/2021 due to a significant increase in the growth index, valuation index and solvency index. Earnings per share increased from -$0.0355 to $0.11, the quick ratio increased from 0.23 to 0.39, and debt to equity declined from 3.41 to 1.15.
Blonder Tongue Laboratories, Inc. (BDR) was upgraded to D+ from D on 10/13/2021 due to a significant increase in the growth index, valuation index and solvency index. Earnings per share increased from -$0.0355 to $0.11, the quick ratio increased from 0.23 to 0.39, and debt to equity declined from 3.41 to 1.15.
D
Sell
3/26/2021Upgraded
Blonder Tongue Laboratories, Inc. (BDR) was upgraded to D from D- on 3/26/2021 due to an increase in the volatility index.
Blonder Tongue Laboratories, Inc. (BDR) was upgraded to D from D- on 3/26/2021 due to an increase in the volatility index.
D
Sell
12/3/2020Downgrade
Blonder Tongue Laboratories, Inc. (BDR) was downgraded to D- from D on 12/3/2020 due to a decline in the solvency index, valuation index and efficiency index. Debt to equity increased from 0.9 to 1.4, net income declined 49.66% from -$1.19M to -$1.79M, and total capital declined 17.3% from $12.13M to $10.03M.
Blonder Tongue Laboratories, Inc. (BDR) was downgraded to D- from D on 12/3/2020 due to a decline in the solvency index, valuation index and efficiency index. Debt to equity increased from 0.9 to 1.4, net income declined 49.66% from -$1.19M to -$1.79M, and total capital declined 17.3% from $12.13M to $10.03M.
D
Sell
6/4/2020Upgraded
Blonder Tongue Laboratories, Inc. (BDR) was upgraded to D from D- on 6/4/2020 due to an increase in the volatility index.
Blonder Tongue Laboratories, Inc. (BDR) was upgraded to D from D- on 6/4/2020 due to an increase in the volatility index.
D
Sell
5/20/2020Downgrade
Blonder Tongue Laboratories, Inc. (BDR) was downgraded to D- from D on 5/20/2020 due to a major decline in the efficiency index, solvency index and volatility index. Debt to equity increased from 0.47 to 0.72, the quick ratio declined from 0.37 to 0.26, and total capital declined 13.31% from $13.47M to $11.68M.
Blonder Tongue Laboratories, Inc. (BDR) was downgraded to D- from D on 5/20/2020 due to a major decline in the efficiency index, solvency index and volatility index. Debt to equity increased from 0.47 to 0.72, the quick ratio declined from 0.37 to 0.26, and total capital declined 13.31% from $13.47M to $11.68M.
D
Sell
4/14/2020Downgrade
Blonder Tongue Laboratories, Inc. (BDR) was downgraded to D from C on 4/14/2020 due to a significant decline in the valuation index, efficiency index and growth index. EBIT declined 191.97% from -$1.28M to -$3.75M, net income declined 188.01% from -$1.33M to -$3.84M, and earnings per share declined from -$0.14 to -$0.3994.
Blonder Tongue Laboratories, Inc. (BDR) was downgraded to D from C on 4/14/2020 due to a significant decline in the valuation index, efficiency index and growth index. EBIT declined 191.97% from -$1.28M to -$3.75M, net income declined 188.01% from -$1.33M to -$3.84M, and earnings per share declined from -$0.14 to -$0.3994.
C
Hold
8/30/2019Downgrade
Blonder Tongue Laboratories, Inc. (BDR) was downgraded to C from C+ on 8/30/2019 due to a decline in the total return index and volatility index.
Blonder Tongue Laboratories, Inc. (BDR) was downgraded to C from C+ on 8/30/2019 due to a decline in the total return index and volatility index.
C
Hold
8/15/2019Upgraded
Blonder Tongue Laboratories, Inc. (BDR) was upgraded to C+ from C on 8/15/2019 due to an increase in the growth index and solvency index. Operating cash flow increased 55.32% from -$3.02M to -$1.35M, EBIT increased 52.18% from -$1.77M to -$845, and total revenue increased 33.19% from $4.08M to $5.44M.
Blonder Tongue Laboratories, Inc. (BDR) was upgraded to C+ from C on 8/15/2019 due to an increase in the growth index and solvency index. Operating cash flow increased 55.32% from -$3.02M to -$1.35M, EBIT increased 52.18% from -$1.77M to -$845, and total revenue increased 33.19% from $4.08M to $5.44M.
C
Hold
5/16/2019Upgraded
Blonder Tongue Laboratories, Inc. (BDR) was upgraded to C from D on 5/16/2019 due to a significant increase in the valuation index, efficiency index and growth index. Net income increased 817.65% from -$742 to $5.33M, earnings per share increased from -$0.0816 to $0.53, and total capital increased 27.88% from $13.02M to $16.65M.
Blonder Tongue Laboratories, Inc. (BDR) was upgraded to C from D on 5/16/2019 due to a significant increase in the valuation index, efficiency index and growth index. Net income increased 817.65% from -$742 to $5.33M, earnings per share increased from -$0.0816 to $0.53, and total capital increased 27.88% from $13.02M to $16.65M.
D
Sell
5/8/2019Downgrade
Blonder Tongue Laboratories, Inc. (BDR) was downgraded to D from D+ on 5/8/2019 due to a noticeable decline in the total return index.
Blonder Tongue Laboratories, Inc. (BDR) was downgraded to D from D+ on 5/8/2019 due to a noticeable decline in the total return index.
D
Sell
4/3/2019Downgrade
Blonder Tongue Laboratories, Inc. (BDR) was downgraded to D+ from C- on 4/3/2019 due to a substantial decline in the growth index and solvency index. EBIT declined 1,445.45% from -$44 to -$680, earnings per share declined from -$0.0215 to -$0.0816, and the quick ratio declined from 0.6 to 0.39.
Blonder Tongue Laboratories, Inc. (BDR) was downgraded to D+ from C- on 4/3/2019 due to a substantial decline in the growth index and solvency index. EBIT declined 1,445.45% from -$44 to -$680, earnings per share declined from -$0.0215 to -$0.0816, and the quick ratio declined from 0.6 to 0.39.
C
Hold
3/4/2019Upgraded
Blonder Tongue Laboratories, Inc. (BDR) was upgraded to C- from D+ on 3/4/2019 due to an increase in the total return index, growth index and efficiency index. EBIT increased 79.72% from -$217 to -$44, earnings per share increased from -$0.0376 to -$0.0215, and net income increased 40.6% from -$335 to -$199.
Blonder Tongue Laboratories, Inc. (BDR) was upgraded to C- from D+ on 3/4/2019 due to an increase in the total return index, growth index and efficiency index. EBIT increased 79.72% from -$217 to -$44, earnings per share increased from -$0.0376 to -$0.0215, and net income increased 40.6% from -$335 to -$199.
D
Sell
11/6/2018Downgrade
Blonder Tongue Laboratories, Inc. (BDR) was downgraded to D+ from C- on 11/6/2018 due to a large decline in the total return index.
Blonder Tongue Laboratories, Inc. (BDR) was downgraded to D+ from C- on 11/6/2018 due to a large decline in the total return index.
C
Hold
9/24/2018Downgrade
Blonder Tongue Laboratories, Inc. (BDR) was downgraded to C- from C on 9/24/2018 due to a large decline in the total return index.
Blonder Tongue Laboratories, Inc. (BDR) was downgraded to C- from C on 9/24/2018 due to a large decline in the total return index.
C
Hold
8/15/2018Upgraded
Blonder Tongue Laboratories, Inc. (BDR) was upgraded to C from C- on 8/15/2018 due to a substantial increase in the growth index, total return index and efficiency index. Operating cash flow increased 61.19% from $505 to $814.
Blonder Tongue Laboratories, Inc. (BDR) was upgraded to C from C- on 8/15/2018 due to a substantial increase in the growth index, total return index and efficiency index. Operating cash flow increased 61.19% from $505 to $814.
C
Hold
7/13/2018Upgraded
Blonder Tongue Laboratories, Inc. (BDR) was upgraded to C- from D+ on 7/13/2018 due to a substantial increase in the total return index and volatility index.
Blonder Tongue Laboratories, Inc. (BDR) was upgraded to C- from D+ on 7/13/2018 due to a substantial increase in the total return index and volatility index.
D
Sell
6/5/2018Upgraded
Blonder Tongue Laboratories, Inc. (BDR) was upgraded to D+ from D on 6/5/2018 due to an increase in the total return index and volatility index.
Blonder Tongue Laboratories, Inc. (BDR) was upgraded to D+ from D on 6/5/2018 due to an increase in the total return index and volatility index.
D
Sell
5/11/2018Downgrade
Blonder Tongue Laboratories, Inc. (BDR) was downgraded to D from D+ on 5/11/2018 due to a large decline in the growth index and valuation index. Earnings per share declined from $0.0305 to -$0.01, EBIT declined 77.11% from $380 to $87, and total revenue declined 3.72% from $5.57M to $5.36M.
Blonder Tongue Laboratories, Inc. (BDR) was downgraded to D from D+ on 5/11/2018 due to a large decline in the growth index and valuation index. Earnings per share declined from $0.0305 to -$0.01, EBIT declined 77.11% from $380 to $87, and total revenue declined 3.72% from $5.57M to $5.36M.
D
Sell
4/4/2018Upgraded
Blonder Tongue Laboratories, Inc. (BDR) was upgraded to D+ from D on 4/4/2018 due to an increase in the solvency index, total return index and efficiency index. Net income increased 267.32% from -$153 to $256, the quick ratio increased from 0.6 to 0.71, and debt to equity declined from 0.98 to 0.87.
Blonder Tongue Laboratories, Inc. (BDR) was upgraded to D+ from D on 4/4/2018 due to an increase in the solvency index, total return index and efficiency index. Net income increased 267.32% from -$153 to $256, the quick ratio increased from 0.6 to 0.71, and debt to equity declined from 0.98 to 0.87.
D
Sell
5/1/2017Downgrade
Blonder Tongue Laboratories, Inc. (BDR) was downgraded to D from D+ on 5/1/2017 due to a decline in the total return index and volatility index.
Blonder Tongue Laboratories, Inc. (BDR) was downgraded to D from D+ on 5/1/2017 due to a decline in the total return index and volatility index.
D
Sell
4/3/2017Upgraded
Blonder Tongue Laboratories, Inc. (BDR) was upgraded to D+ from D on 4/3/2017 due to a substantial increase in the total return index, growth index and volatility index. Earnings per share increased from -$0.083 to -$0.0417, EBIT increased 29.47% from -$414 to -$292, and total revenue increased 0.31% from $5.43M to $5.45M.
Blonder Tongue Laboratories, Inc. (BDR) was upgraded to D+ from D on 4/3/2017 due to a substantial increase in the total return index, growth index and volatility index. Earnings per share increased from -$0.083 to -$0.0417, EBIT increased 29.47% from -$414 to -$292, and total revenue increased 0.31% from $5.43M to $5.45M.
D
Sell
8/17/2016Upgraded
Blonder Tongue Laboratories Inc. (BDR) was upgraded to D from D- on 8/17/2016 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 2,964.71% from -$17 to $487, EBIT increased 217.5% from -$200 to $235, and earnings per share increased from -$0.0426 to $0.01.
Blonder Tongue Laboratories Inc. (BDR) was upgraded to D from D- on 8/17/2016 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 2,964.71% from -$17 to $487, EBIT increased 217.5% from -$200 to $235, and earnings per share increased from -$0.0426 to $0.01.
D
Sell
3/11/2016Downgrade
Blonder Tongue Laboratories Inc. (BDR) was downgraded to D- from D on 3/11/2016 due to a major decline in the volatility index and total return index.
Blonder Tongue Laboratories Inc. (BDR) was downgraded to D- from D on 3/11/2016 due to a major decline in the volatility index and total return index.
D
Sell
1/15/2016Downgrade
Blonder Tongue Laboratories Inc. (BDR) was downgraded to D from D+ on 1/15/2016 due to a noticeable decline in the total return index.
Blonder Tongue Laboratories Inc. (BDR) was downgraded to D from D+ on 1/15/2016 due to a noticeable decline in the total return index.
D
Sell
12/31/2015Upgraded
Blonder Tongue Laboratories Inc. (BDR) was upgraded to D+ from D on 12/31/2015 due to a large increase in the total return index, valuation index and volatility index.
Blonder Tongue Laboratories Inc. (BDR) was upgraded to D+ from D on 12/31/2015 due to a large increase in the total return index, valuation index and volatility index.
D
Sell
6/24/2015Downgrade
Blonder Tongue Laboratories Inc. (BDR) was downgraded to D from D+ on 6/24/2015 due to a major decline in the total return index, solvency index and volatility index.
Blonder Tongue Laboratories Inc. (BDR) was downgraded to D from D+ on 6/24/2015 due to a major decline in the total return index, solvency index and volatility index.
D
Sell
5/15/2015Downgrade
Blonder Tongue Laboratories Inc. (BDR) was downgraded to D+ from C- on 5/15/2015 due to a significant decline in the volatility index, growth index and total return index. Operating cash flow declined 66.85% from -$1.09M to -$362, and total revenue declined 21.8% from $6.06M to $4.74M.
Blonder Tongue Laboratories Inc. (BDR) was downgraded to D+ from C- on 5/15/2015 due to a significant decline in the volatility index, growth index and total return index. Operating cash flow declined 66.85% from -$1.09M to -$362, and total revenue declined 21.8% from $6.06M to $4.74M.
C
Hold
3/31/2015Downgrade
Blonder Tongue Laboratories Inc. (BDR) was downgraded to C- from C on 3/31/2015 due to a significant decline in the growth index, volatility index and total return index. Earnings per share declined from $0.09 to -$0.1078, EBIT declined 177.49% from $653 to -$506, and operating cash flow declined 146.97% from $2.33M to -$1.09M.
Blonder Tongue Laboratories Inc. (BDR) was downgraded to C- from C on 3/31/2015 due to a significant decline in the growth index, volatility index and total return index. Earnings per share declined from $0.09 to -$0.1078, EBIT declined 177.49% from $653 to -$506, and operating cash flow declined 146.97% from $2.33M to -$1.09M.
C
Hold
11/14/2014Upgraded
Blonder Tongue Laboratories Inc. (BDR) was upgraded to C from C- on 11/14/2014 due to a significant increase in the growth index, volatility index and total return index. EBIT increased 93.77% from $337 to $653, and earnings per share increased from $0.0558 to $0.09.
Blonder Tongue Laboratories Inc. (BDR) was upgraded to C from C- on 11/14/2014 due to a significant increase in the growth index, volatility index and total return index. EBIT increased 93.77% from $337 to $653, and earnings per share increased from $0.0558 to $0.09.
C
Hold
8/27/2014Upgraded
Blonder Tongue Laboratories Inc. (BDR) was upgraded to C- from D+ on 8/27/2014 due to a noticeable increase in the volatility index, total return index and solvency index.
Blonder Tongue Laboratories Inc. (BDR) was upgraded to C- from D+ on 8/27/2014 due to a noticeable increase in the volatility index, total return index and solvency index.
D
Sell
8/15/2014Upgraded
Blonder Tongue Laboratories Inc. (BDR) was upgraded to D+ from D on 8/15/2014 due to a noticeable increase in the growth index and efficiency index. Total revenue increased 58.26% from $5.58M to $8.83M, and total capital increased 4.65% from $19.28M to $20.17M.
Blonder Tongue Laboratories Inc. (BDR) was upgraded to D+ from D on 8/15/2014 due to a noticeable increase in the growth index and efficiency index. Total revenue increased 58.26% from $5.58M to $8.83M, and total capital increased 4.65% from $19.28M to $20.17M.
D
Sell
5/16/2014Downgrade
Blonder Tongue Laboratories Inc. (BDR) was downgraded to D from D+ on 5/16/2014 due to a substantial decline in the growth index, efficiency index and solvency index. The quick ratio declined from 0.9 to 0.34, operating cash flow declined 25.96% from $520 to $385, and total revenue declined 22.33% from $7.18M to $5.58M.
Blonder Tongue Laboratories Inc. (BDR) was downgraded to D from D+ on 5/16/2014 due to a substantial decline in the growth index, efficiency index and solvency index. The quick ratio declined from 0.9 to 0.34, operating cash flow declined 25.96% from $520 to $385, and total revenue declined 22.33% from $7.18M to $5.58M.
OTC PK
04/23/2024 11:35AM Eastern
Quotes delayed
